Phase 2 sacituzumab govitecan (TROP2 ADC) ± ivonescimab (PD-1×VEGF bispecific) in AGA+ NSCLC
Trial status
Currently Recruiting
Status as of
Got an update?- Trial ID
- NCT07393555 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer (NSCLC)
- Stage of research
- Exploratory
- Location
- CA, GA, ID, IL, MI, MO, MT, NH, OH, VT, WI (US, multi-center)
- Published in
- New in Oncology - Nov 19, 2026
This randomized Phase 2 Lung-MAP sub-study (SWOG Cancer Research Network) tests whether adding ivonescimab to sacituzumab govitecan improves outcomes versus either agent alone in previously treated, stage IV or recurrent NSCLC with an actionable genomic alteration (ALK, EGFR, HER2/ERBB2, MET, NTRK, RET, or ROS1), after appropriate targeted therapy and platinum-based chemotherapy and without prior PD-1/PD-L1 therapy. Sacituzumab govitecan (Gilead Sciences) is a TROP2-targeted antibody–drug conjugate that delivers SN-38 (a topoisomerase I inhibitor payload) into tumor cells, aiming to extend activity beyond driver-targeted TKIs. Ivonescimab (Akeso) is a PD-1×VEGF bispecific antibody intended to both release immune inhibition and suppress tumor angiogenesis, a dual mechanism designed to deepen and prolong responses compared with PD-1 blockade alone. The key commercial/scientific angle is a “post-targeted-therapy” strategy for AGA+ disease, where many patients have already exhausted genotype-matched TKIs and then move to platinum-based chemotherapy ± immunotherapy, followed by single-agent chemo and/or docetaxel-based combinations; this trial asks whether an ADC and an IO/anti-VEGF bispecific can reset disease control after prior targeted therapy and platinum-based chemotherapy.
More in non-small cell lung cancer
-
New trial · Nov 19, 2026 · NCT07756645
Phase 3 ABBV-1480 PD-1×VEGF bispecific antibody vs pembrolizumab in 1L sqNSCLC -
New trial · Nov 19, 2026 · NCT07899801
Phase 1a/1b zanidatamab (HER2 bispecific antibody) + zongertinib (HER2 TKI) in HER2-mutated NSCLC -
New trial · Nov 12, 2026 · NCT07874490
Phase 2 osimertinib EGFR inhibitor plus cyclosporine A calcineurin/NFAT inhibitor in EGFR-mutant NSCLC -
New trial · Nov 12, 2026 · NCT07871214
Phase 2 pumitamig PD‑L1×VEGF‑A bispecific antibody neoadjuvant platform in resectable NSCLC. -
New trial · Nov 12, 2026 · NCT07864584
Phase 1/2 NHT102 inhaled azacitidine DNA hypomethylating agent (DNMT inhibitor) in NSCLC
